Most big pharma companies are now investing in digital technology to open up clinical trials to more patients via remote monitoring technology ... more efficient and patient and investigator ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price target of ...

In its first earnings report since the departure of longtime CEO Joe Kiani, Masimo said Tuesday it is focused on reducing spending to drive long-term growth. The company continues to evaluate ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

User-friendly touch-screen patient monitor measures ECG, SpO 2, NIBP, heart rate, temperature and respiration. Offers optional dual IBP, and EtCo 2 — Now with Masimo SET ® Pulse Oximetry!

In the final rule, CMS repeatedly expressed that it will continue to evaluate and monitor patient safety, access, safeguards, and other topics related to remote direct supervision. Healthcare ...

Between 2021 and 2028 it is projected the remote patient monitoring (RPM) sector will grow nearly three times by revenue. An ...